NASH Drug Pipeline: Why Current Approval Standards Miss the Mark

What They Found

This comprehensive review maps the current and emerging therapeutic landscape for NASH (now termed MASH - Metabolic Dysfunction-Associated Steatohepatitis). The authors detail how resmetirom became the first FDA-approved NASH-specific therapy in 2024, while highlighting dozens of compounds in various pipeline stages targeting different pathways.

Why It Matters

The NASH therapeutic space illustrates a fundamental problem in metabolic medicine: we're optimizing for the wrong endpoints. Resmetirom, a thyroid hormone receptor-β agonist, gained approval based on histological improvement - essentially making liver biopsies look better. But NASH isn't just a liver disease; it's a manifestation of systemic metabolic dysfunction involving insulin resistance, lipid dysregulation, and chronic inflammation.

The pipeline compounds reflect this mechanistic diversity. GLP-1 receptor agonists like semaglutide target the incretin system and show promise for both weight loss and hepatic fat reduction. FGF21 analogs aim to restore metabolic flexibility. PPAR agonists attempt to improve insulin sensitivity and lipid metabolism. Yet most trials still focus on liver-specific outcomes rather than comprehensive metabolic restoration.

This creates a disconnect. A patient might achieve histological NASH resolution while remaining insulin resistant, dyslipidemic, and metabolically inflexible - the very conditions that drove NASH development in the first place. We're treating the symptom while ignoring the underlying metabolic machinery.

What I'd Watch For

The real question isn't which drug improves liver histology fastest, but which interventions restore fundamental metabolic health. Look for trials measuring insulin sensitivity indices (HOMA-IR, Matsuda index), metabolic flexibility markers, and systemic inflammation rather than just ALT levels and fibrosis scores.

The combination therapy approaches mentioned here make mechanistic sense - targeting multiple pathways simultaneously. But without proper metabolic endpoints, we won't know if we're actually fixing the underlying problem or just cosmetically improving liver appearance.

Bottom Line

NASH drug development is solving the wrong problem. Until we shift focus from liver-centric to metabolism-centric outcomes, approved therapies will remain symptomatic treatments rather than curative interventions. The real breakthrough will come when we start measuring and targeting the metabolic dysfunction that drives the disease.